| Identification | Back Directory | [Name]
Dehydrocorydaline | [CAS]
30045-16-0 | [Synonyms]
dehydeocorydaline
Dehydrocorydaline
13-Methylpalmatine
DEHYDROCORYDALINE98%
13-Methyl-2,3,9,10-tetramethoxy-5,6-dihydrodibenzo[a,g]quinolizinium
5,6-Dihydro-2,3,9,10-tetramethoxy-13-methyldibenzo[a,g]quinolizinium
Dibenzo[a,g]quinolizinium,5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl- | [Molecular Formula]
C22H24NO4 | [MDL Number]
MFCD00887635 | [MOL File]
30045-16-0.mol |
| Chemical Properties | Back Directory | [Melting point ]
170-173℃ | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
Cryst. | [color ]
Light yellow to yellow | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow needle crystal powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from Corydalis Corydalis, Yuanhu. | [Uses]
Dehydrocordine has analgesic and sedative effects. It was used for content determination/identification/pharmacological experiments, etc. | [Definition]
ChEBI: Dehydrocorydaline is an alkaloid. | [Biological Activity]
Dehydrocorydaline (13-Methylpalmatine) is an alkaloid isolated from the traditional Chinese medicine Corydalis yanhusuo. It can enhance p38 MAPK activation and has anti-inflammatory and anti-cancer effects. Also Dehydrocorydaline has potent antimalarial effects and low cytotoxicity (cell viability > 90%), P. falciparum 3D7 strain (IC50=38 nM). | [in vitro]
Dehydrocorydaline (0-200 μM) treatment significantly inhibits the growth of MCF-7 cells in a dose-dependent manner. The cell viability is decreased by approximate 40% after 24 h of 200 μM Dehydrocorydaline.
Dehydrocorydaline (0-200 μM) dose-dependently increases Bax protein expression and decreases Bcl-2 protein expression.
Dehydrocorydaline (0-200 μM) induces activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9.
| [in vivo]
Dehydrocorydaline manifests a low acute toxicity with an LD 50 of about 277.5±19.0 mg/kg body weight in mice following oral administration and 21.1±1.4 mg/kg for intraperitoneal injection. < /p> | [target]
| Bcl-2 < span> | Bax | Caspase-7 | Caspase-8 | PARP | |
|
|